Diagnosis, management, and treatment of hepatitis C: an update.
作者信息
Ghany Marc G, Strader Doris B, Thomas David L, Seeff Leonard B
机构信息
Department of Health and Human Services, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Hepatology. 2009 Apr;49(4):1335-74. doi: 10.1002/hep.22759.
Abstract
摘要
相似文献
1
Diagnosis, management, and treatment of hepatitis C: an update.
Hepatology. 2009 Apr;49(4):1335-74. doi: 10.1002/hep.22759.
2
SASLT practice guidelines: management of hepatitis C virus infection.
Saudi J Gastroenterol. 2012 Sep;18 Suppl(Suppl 1):S1-32. doi: 10.4103/1319-3767.101155.
3
Hepatitis C: Enhancing treatment for hepatitis C among drug users.
Nat Rev Gastroenterol Hepatol. 2011 Jan;8(1):11-3. doi: 10.1038/nrgastro.2010.186. Epub 2010 Nov 30.
4
Clinical decisions. Management of incidental hepatitis C virus infection--polling results.
N Engl J Med. 2009 Jun 4;360(23):e30. doi: 10.1056/NEJMclde0902765.
5
[Hepatitis C].
Rev Med Suisse Romande. 2002 Oct;122(10):507-12.
6
Consensus interferon used to treat prior partial-responders to pegylated interferon plus ribavirin.
Dig Dis Sci. 2011 Oct;56(10):3032-7. doi: 10.1007/s10620-011-1869-6. Epub 2011 Aug 31.
7
Effect of Eradication of HCV on Hepatic Venous Pressure Gradient in HIV-Infected Patients With Compensated HCV-Related Cirrhosis.
J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):e142-4. doi: 10.1097/QAI.0000000000000639.
8
Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
Ann Hepatol. 2013 Mar-Apr;12(2):228-35.
9
Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin.
Transplant Proc. 1998 Aug;30(5):2104-6. doi: 10.1016/s0041-1345(98)00554-5.
10
HBV plus HCV, HCV plus HIV, HBV plus HIV.
Curr Gastroenterol Rep. 2006 Feb;8(1):67-74. doi: 10.1007/s11894-006-0066-9.
引用本文的文献
1
A fully automated, ultrasensitive luminescence cascade sensor to address hepatitis C diagnostic disparity.
Innovation (Camb). 2025 May 15;6(8):100952. doi: 10.1016/j.xinn.2025.100952. eCollection 2025 Aug 4.
2
Tumor Size Does Not Affect Survival Outcomes of Patients Undergoing Resection for a Single Hepatocellular Carcinoma Without Microscopic Vascular Invasion in the Modern Era of Antiviral Therapy.
Dig Dis Sci. 2025 Jul 24. doi: 10.1007/s10620-025-09254-x.
3
Distinct Biomarker Profiles of B-Cell Activation in Metabolic and Viral Hepatic Fibrosis.
Int J Mol Sci. 2025 Jun 20;26(13):5942. doi: 10.3390/ijms26135942.
4
Getting to full disclosure: HCV testing and status disclosure behaviors among PWID and their injecting partners.
BMC Public Health. 2025 May 8;25(1):1707. doi: 10.1186/s12889-025-22781-6.
5
Combination therapy enhances the antiviral activity of IFN-λ against SARS-CoV-2 and MERS-CoV.
Virus Res. 2025 May;355:199560. doi: 10.1016/j.virusres.2025.199560. Epub 2025 Mar 18.
6
Reducing hepatitis C diagnostic disparities with a fully automated deep learning-enabled microfluidic system for HCV antigen detection.
Sci Adv. 2025 Mar 21;11(12):eadt3803. doi: 10.1126/sciadv.adt3803. Epub 2025 Mar 19.
7
Tumor protein 53 gene polymorphism, demographic attributes and associated risk factors among liver cancer patients in Calabar, Nigeria.
BMC Cancer. 2025 Mar 10;25(1):430. doi: 10.1186/s12885-025-13803-y.
8
Liver fibrosis stage classification in stacked microvascular images based on deep learning.
BMC Med Imaging. 2025 Jan 7;25(1):8. doi: 10.1186/s12880-024-01531-x.
9
HLA Class I (A and B) Allele Polymorphism in a Moroccan Population Infected with Hepatitis C Virus.
Curr Issues Mol Biol. 2024 Dec 13;46(12):14080-14094. doi: 10.3390/cimb46120842.
10
Optimizing Hepatitis C Treatment Monitoring: Is Sustained Virologic Response at 4 Weeks Becoming the New Standard?
Microorganisms. 2024 Oct 10;12(10):2050. doi: 10.3390/microorganisms12102050.
本文引用的文献
1
Liver biopsy.
Hepatology. 2009 Mar;49(3):1017-44. doi: 10.1002/hep.22742.
2
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
N Engl J Med. 2008 Dec 4;359(23):2429-41. doi: 10.1056/NEJMoa0707615.
3
Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.
Am J Gastroenterol. 2008 May;103(5):1131-5. doi: 10.1111/j.1572-0241.2008.01793.x.
4
Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
Int J Artif Organs. 2008 Apr;31(4):295-302. doi: 10.1177/039139880803100404.
5
KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease.
Kidney Int Suppl. 2008 Apr(109):S1-99. doi: 10.1038/ki.2008.81.
6
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
JAMA. 2008 Feb 27;299(8):914-24. doi: 10.1001/jama.299.8.914.
7
The impact of disease recurrence on graft survival following liver transplantation: a single centre experience.
Transpl Int. 2008 May;21(5):459-65. doi: 10.1111/j.1432-2277.2007.00628.x. Epub 2008 Jan 21.
8
Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection.
Pediatr Infect Dis J. 2008 Feb;27(2):142-8. doi: 10.1097/INF.0b013e318159836c.
9
Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial.
Hepatology. 2008 Mar;47(3):836-43. doi: 10.1002/hep.22094.
10
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.
Hepatology. 2008 Feb;47(2):605-12. doi: 10.1002/hep.22044.
Zotero 插件